Patents
Literature
14 results about "Major histocompatibility complex" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The major histocompatibility complex (MHC) is a set of genes that code for cell surface proteins essential for the acquired immune system to recognize foreign molecules in vertebrates, which in turn determines histocompatibility. The main function of MHC molecules is to bind to antigens derived from pathogens and display them on the cell surface for recognition by the appropriate T-cells. MHC molecules mediate interactions of leukocytes, also called white blood cells (WBCs), which are immune cells, with other leukocytes or with body cells. The MHC determines compatibility of donors for organ transplant, as well as one's susceptibility to an autoimmune disease via crossreacting immunization. The human MHC is also called the HLA (human leukocyte antigen) complex (often just the HLA). The MHC in mice is called the Histocompatibility system 2 or just the H-2.
T cell receptors
PendingCN122094973AImmunoglobulin superfamilyTumor rejection antigen precursorsImmunogenic peptideImmunogenicity
The present invention provides a T-cell receptor (TCR) that binds to an immunogenic peptide when the peptide is presented by the major histocompatibility complex (MHC).
Owner:OSPEDALE SAN RAFFAELE SRL +1
Peptide search system for immunotherapy
A system for binding peptide search for immunotherapy is presented. The system includes employing a deep neural network to predict a peptide presentation given Major Histocompatibility Complex allele sequences and peptide sequences, training a Variational Autoencoder (VAE) to reconstruct peptides by converting the peptide sequences into continuous embedding vectors, running a Monte Carlo Tree Search to generate a first set of positive peptide vaccine candidates, running a Bayesian Optimization search with the trained VAE and a Backpropagation search with the trained VAE to generate a second set of positive peptide vaccine candidates, using a sampling from a Position Weight Matrix (sPWM) to generate a third set of positive peptide vaccine candidates, screening and merging the first, second, and third sets of positive peptide vaccine candidates, and outputting qualified peptides for immunotherapy from the screened and merged sets of positive peptide vaccine candidates to support downstream clinical decision making.
Owner:NEC CORP
MHC Ib-mediated aquaporin 4 (AQP4)-specific immunosuppression as a novel treatment for NMO
PendingCN122122174APolypeptide with localisation/targeting motifNervous disorderPeptide antigenSpecific immunity
The present invention relates to the therapeutic use of non-classical human major histocompatibility complex (MHC) molecules (also known as MHC class Ib molecules) in combination with a peptide antigen for the treatment of neuromyelitis optica (NMO). More specifically, the present invention relates to recombinant polypeptides comprising a peptide antigen in combination with one or more domains of a non-classical MHC class Ib molecule. The present invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising such recombinant polypeptides, and their use in the treatment of neuromyelitis optica (NMO).
Owner:JULIUS MAXIMILIANS UNIV WURZBURG
T-Cell Modulatory Polypeptides and Methods of Use Thereof
The present disclosure provides a peptide-major histocompatibility complex (pMHC) polypeptide comprising a peptide epitope and class I MHC polypeptides. The present disclosure provides fusion molecules comprising a pMHC polypeptide and a heterologous fusion partner. The present disclosure provides single-chain T-cell modulatory polypeptides that comprise a pMHC polypeptide, one or more immunomodulatory polypeptide, and an immunoglobulin (Ig) Fc or a non-Ig scaffold. A TMP is useful for modulating the activity of a T cell, and for modulating an immune response in an individual.
Owner:CUE BIOPHARMA INC
Method and assay device for predicting t cell activation of peptide-mhc
This method for predicting T cell activation via peptide-MHC includes the following steps: wherein the analytical device: receives genetic data from a patient; identifies, based on the genetic data, the first amino acid sequence of the major histocompatibility complex (MHC) and the second amino acid sequence of an antigen produced by tumor cells; generates a matrix indicating the interrelationship between the first and second amino acid sequences in units of individual amino acids; and inputs the matrix into a trained neural network model to determine whether T cells secrete at least a threshold amount of cytokines due to the binding of MHC to the antigen.
Owner:PETMEDIX GMBH +1
T cell receptors targeting npm1 neoantigens
PendingCN122122172AImmunoglobulin superfamilyGenetically modified cellsAntigen Binding FragmentCellular receptor
Provided herein are T cell receptors (TCRs) or antigen-binding fragments thereof, such as those that recognize or bind NPM1c neoantigens. In particular, the present disclosure relates to TCRs that bind or recognize specific NPM1c peptides in the context of major histocompatibility complex (MHC) molecules. The present disclosure also relates to nucleic acids encoding such TCRs, engineered cells comprising such TCRs, methods of isolating such TCRs, and uses thereof, e.g., in cell therapy.
Owner:BRUCEFIELD BIOTECHNOLOGY CO LTD
Engineered regulatory T cell
The present invention relates to an engineered regulatory T cell (Treg) comprising a T cell receptor (TCR) which is capable of specifically binding to a myelin basic protein (MBP) peptide or variant or fragment thereof when the peptide is presented by a major histocompatibility complex (MHC) molecule. The present invention further relates to methods for providing an engineered Treg and to methods and uses of said engineered Treg and vectors and kits of vectors encoding said Treg.
Owner:UCL BUSINESS LTD
Fucosylation and immune modulation in cancer
Disclosed are methods for treating a cancer and / or modulating immune CD4+ T cell mediated therapies comprising administering to a subject a fucose. In one aspect, disclosed herein are methods of modulating major histocompatibility complex II human lymphocyte antigen (HLA)-DRB 1 expression on the surface of a cell comprising contacting the cell with an agent that modulates the amount of fucosylation on the cell; wherein an increase in fucosylation increases surface expression of HLA-DRB 1; and wherein a decrease in fucosylation decreases the surface expression of HLA-DRB 1.
Owner:H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC
T cell receptor and use thereof
Provided is an HLA-independent T cell receptor. This major histocompatibility complex class I-related molecule 1 (MR1)-restricted T cell receptor (TCR) comprises a TCRα chain that includes a CDR3 having a specific amino acid sequence and is encoded by a specific nucleotide sequence and a TCRβ chain that includes a CDR3 having a specific amino acid sequence and is encoded by a specific nucleotide sequence. This TCR specifically recognizes an antigen expressed in breast cancer cells.
Owner:UNIVERSITY OF TOYAMA
Method for selecting subject-derived neoantigen
PendingUS20260142009A1Tumor rejection antigen precursorsDrug and medicationsGenes mutationCancer cell
The purpose of the present invention is to provide a means for selecting subject-derived neoantigens. The above problem is solved by providing a method for selecting a subject-derived neoantigen, said method comprising: a step of acquiring sequence data of a normal cell and a cancer cell derived from a subject, a step of identifying a gene having a genetic mutation specific to the cancer cell, and a step of identifying a peptide based on a wild-type gene corresponding to the gene having the genetic mutation specific to the cancer cell from a major histocompatibility complex (MHC)-presented peptide database, wherein the genetic mutation is a missense mutation, and the peptide based on the wild-type gene corresponding to the gene having the genetic mutation has a wild-type amino acid corresponding to the position of an amino acid mutation due to the genetic mutation.
Owner:SAPPORO MEDICAL UNIVERSITY
Mhcb-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and moe antibody disease
PendingCN122138974APeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsPeptide antigenDisease
This invention relates to the therapeutic use of non-classical human major histocompatibility complex (MHC) molecules (also known as MHC class Ib molecules) in combination with myelin-associated peptide antigens for the treatment of multiple sclerosis (MS), MOG antibody disease, and MOG antibody-positive neuromyelitis optica. More specifically, this invention relates to recombinant polypeptides comprising a peptide antigen and one or more domains of a non-classical MHC class Ib molecule. The invention also relates to methods for preparing such recombinant polypeptides, pharmaceutical compositions comprising such recombinant polypeptides, and their use for the treatment of multiple sclerosis (MS), MOG antibody disease, and MOG antibody-positive neuromyelitis optica.
Owner:JULIUS MAXIMILIANS UNIV WURZBURG
Ultrabright fluorescent nanocomposite structures for enhanced fluorescent bioassays
PendingUS20260153444A1Material nanotechnologyNanoopticsSurface plasmonic resonanceLocalized surface plasmon
Described herein is a fluorescent nanocomposite. The fluorescent nanocomposite structure may include a plasmonic nanostructure comprising having at least one localized surface plasmon resonance wavelength (λLSPR), at least one spacer coating, at least one fluorescent agent having a maximum excitation wavelength (λEX), and at least one peptide-loaded major histocompatibility complex (MHC) molecule (pMHC). The fluorescent nanocomposite structure has a fluorescent intensity that is at least 500 times greater than a fluorescent intensity of the at least one fluorescent agent alone.
Owner:AURAGENT BIOSCIENCE LLC
Composition comprising antigen presenting cell co-expressing MHC and tumor antigen and treatment of cancer using the same
The present invention relates to a vaccine composition for cancer prevention or treatment comprising an antigen-presenting cell in which a complex of MHC (major histocompatibility complex) and a tumor antigen is overexpressed on the cell surface, and to cancer treatment using the same.
Owner:LG CHEM LTD
Genetically modified mice expressing chimeric major histocompatibility complex (MHC) ii molecules
Owner:REGENERON PHARMACEUTICALS INC